专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060257450A1 Drug delivery systems for treatment of diseases or conditions 审中-公开
标题翻译：用于治疗疾病或病症的药物输送系统
公开(公告)号：US20060257450A1
公开(公告)日：2006-11-16
申请号：US11386290
申请日：2006-03-21
申请人： Sreenivasu Mudumba , Philippe Jm Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
发明人： Sreenivasu Mudumba , Philippe Jm Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
IPC分类号： A61K31/4745 , A61F2/02
CPC分类号： A61K9/0051 , A61K31/436 , A61K31/4745
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of therapeutic agents to such tissues. A solid drug delivery system may be placed in a subject, including but not limited to placement between the sclera and the conjunctiva or transscleral placement. Described methods may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, age-related macular degeneration, or wet age-related macular degeneration in a subject. The solid drug delivery devices may comprise rapamycin or other therapeutic agents. Also described are methods of treating ocular diseases or disorders by administering an antiproliferative agent, including but not limited to rapamycin, proximal to an ocular device.
摘要翻译：包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。本文描述的是用于向这些组织提供治疗剂的延长递送的固体药物递送系统和方法。固体药物递送系统可以放置在受试者中，包括但不限于在巩膜和结膜之间的放置或经巩膜放置。描述的方法可用于施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成，年龄相关性黄斑变性或湿性年龄相关性黄斑变性。固体药物递送装置可以包含雷帕霉素或其它治疗剂。还描述了通过在近视眼装置上施用抗增生剂（包括但不限于雷帕霉素）来治疗眼部疾病或病症的方法。

2. 发明申请

US20060264453A1 Rapamycin formulations and methods of their use 有权
标题翻译：雷帕霉素配方及其使用方法
公开(公告)号：US20060264453A1
公开(公告)日：2006-11-23
申请号：US11352092
申请日：2006-02-09
申请人： Sreenivasu Mudumba , Philippe Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
发明人： Sreenivasu Mudumba , Philippe Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
IPC分类号： A61K31/4745 , A61K31/045
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
摘要翻译：本文描述的是液体雷帕霉素制剂。本文描述了使用本文所述的液体雷帕霉素制剂治疗或预防疾病或病症如脉络膜新生血管形成，湿性AMD和干性AMD的方法，以及防止干性AMD转变为湿性AMD。

3. 发明申请

US20060258698A1 Liquid formulations for treatment of diseases or conditions 审中-公开
公开(公告)号：US20060258698A1
公开(公告)日：2006-11-16
申请号：US11351761
申请日：2006-02-09
申请人： Sreenivasu Mudumba , Philippe Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
发明人： Sreenivasu Mudumba , Philippe Dor , Thierry Nivaggioli , David Weber , Sidiq Farooq
IPC分类号： A61K31/4745
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.

4. 发明授权

US08367097B2 Liquid formulations for treatment of diseases or conditions 有权
标题翻译：用于治疗疾病或病症的液体制剂
公开(公告)号：US08367097B2
公开(公告)日：2013-02-05
申请号：US12778872
申请日：2010-05-12
申请人： Sreenivasu Mudumba , Philippe J M Dor , Thierry Nivaggioli , David A. Weber , Sidiq Farooq
发明人： Sreenivasu Mudumba , Philippe J M Dor , Thierry Nivaggioli , David A. Weber , Sidiq Farooq
IPC分类号： A61F2/00 , A01N43/62 , A61K31/55 , A61K38/13
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.
摘要翻译：包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。本文描述的是液体制剂，其将多种治疗剂（包括但不限于雷帕霉素）递送给受试者较长时间; 当被置于受试者的水性介质中时形成非分散物质的液体制剂; 在水性介质中形成凝胶或凝胶状物质的非分散质量形成液体制剂; 液体制剂，包含治疗剂和多种聚合物; 以及使用液体制剂将治疗剂递送给受试者较长时间的方法。液体制剂可以放置在受试者的水性介质中，包括但不限于通过眼内或眼周内施用，或靠近受试者待治疗的疾病或病症的位置放置。可以使用方法来施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成或年龄相关性黄斑变性或湿性年龄相关性黄斑变性。液体制剂可以包含雷帕霉素或其它治疗剂。

5. 发明申请

US20090074786A1 FORMULATIONS FOR TREATING OCULAR DISEASES AND CONDITIONS 有权
标题翻译：治疗卵巢疾病和病症的制剂
公开(公告)号：US20090074786A1
公开(公告)日：2009-03-19
申请号：US12193686
申请日：2008-08-18
申请人： Philippe J.M. Dor , Sreenivasu Mudumba , Thierry Nivaggioli , David A. Weber , Sidiq Farooq , Sudeep K. Takhar
发明人： Philippe J.M. Dor , Sreenivasu Mudumba , Thierry Nivaggioli , David A. Weber , Sidiq Farooq , Sudeep K. Takhar
IPC分类号： A61K31/436 , A61P27/02 , A61K39/395
CPC分类号： A61K31/436
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.
摘要翻译：包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。本文描述的是液体制剂，其将多种治疗剂（包括但不限于雷帕霉素）递送给受试者较长时间; 当被置于受试者的水性介质中时形成非分散物质的液体制剂; 在水性介质中形成凝胶或凝胶状物质的非分散质量形成液体制剂; 液体制剂，包含治疗剂和多种聚合物; 以及使用液体制剂将治疗剂递送给受试者较长时间的方法。液体制剂可以放置在受试者的水性介质中，包括但不限于通过眼内或眼周内施用，或靠近受试者待治疗的疾病或病症的位置放置。可以使用方法来施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成或年龄相关性黄斑变性或湿性年龄相关性黄斑变性。液体制剂可以包含雷帕霉素或其它治疗剂。

6. 发明授权

US08663639B2 Formulations for treating ocular diseases and conditions 有权
标题翻译：用于治疗眼部疾病和病症的制剂
公开(公告)号：US08663639B2
公开(公告)日：2014-03-04
申请号：US12193686
申请日：2008-08-18
申请人： Philippe J. M. Dor , Sreenivasu Mudumba , Thierry Nivaggioli , David A. Weber , Sidiq Farooq , Sudeep Takhar
发明人： Philippe J. M. Dor , Sreenivasu Mudumba , Thierry Nivaggioli , David A. Weber , Sidiq Farooq , Sudeep Takhar
IPC分类号： A61K39/395 , A61K31/44 , A01N43/42
CPC分类号： A61K31/436
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.
摘要翻译：包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。本文描述的是液体制剂，其将多种治疗剂（包括但不限于雷帕霉素）递送给受试者较长时间; 当被置于受试者的水性介质中时形成非分散物质的液体制剂; 在水性介质中形成凝胶或凝胶状物质的非分散质量形成液体制剂; 液体制剂，包含治疗剂和多种聚合物; 以及使用液体制剂将治疗剂递送给受试者较长时间的方法。液体制剂可以放置在受试者的水性介质中，包括但不限于通过眼内或眼周内施用，或靠近受试者待治疗的疾病或病症的位置放置。可以使用方法来施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成或年龄相关性黄斑变性或湿性年龄相关性黄斑变性。液体制剂可以包含雷帕霉素或其它治疗剂。

7. 发明授权

US08637070B2 Rapamycin formulations and methods of their use 有权
标题翻译：雷帕霉素配方及其使用方法
公开(公告)号：US08637070B2
公开(公告)日：2014-01-28
申请号：US11352092
申请日：2006-02-09
申请人： Sreenivasu Mudumba , Philippe J M Dor , Thierry Nivaggioli , David A. Weber , Sidiq Farooq
发明人： Sreenivasu Mudumba , Philippe J M Dor , Thierry Nivaggioli , David A. Weber , Sidiq Farooq
IPC分类号： A61K9/00 , A61F2/00
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
摘要翻译：本文描述的是液体雷帕霉素制剂。本文描述了使用本文所述的液体雷帕霉素制剂治疗或预防疾病或病症如脉络膜新生血管形成，湿性AMD和干性AMD的方法，以及防止干性AMD转变为湿性AMD。

8. 发明申请

US20100227879A1 LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS 有权
标题翻译：用于治疗疾病或病症的液体制剂
公开(公告)号：US20100227879A1
公开(公告)日：2010-09-09
申请号：US12778872
申请日：2010-05-12
申请人： Sreenivasu Mudumba , Philippe J.M. Dor , Thierry Nivaggioli , David A. Weber , Sidiq Farooq
发明人： Sreenivasu Mudumba , Philippe J.M. Dor , Thierry Nivaggioli , David A. Weber , Sidiq Farooq
IPC分类号： A61K31/436 , A61P27/02
CPC分类号： A61K9/0046 , A61K9/0019 , A61K9/0048 , A61K31/045 , A61K31/436 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.
摘要翻译：包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。本文描述的是液体制剂，其将多种治疗剂（包括但不限于雷帕霉素）递送给受试者较长时间; 当被置于受试者的水性介质中时形成非分散物质的液体制剂; 在水性介质中形成凝胶或凝胶状物质的非分散质量形成液体制剂; 液体制剂，包含治疗剂和多种聚合物; 以及使用液体制剂将治疗剂递送给受试者较长时间的方法。液体制剂可以放置在受试者的水性介质中，包括但不限于通过眼内或眼周内施用，或靠近受试者待治疗的疾病或病症的位置放置。可以使用方法来施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成或年龄相关性黄斑变性或湿性年龄相关性黄斑变性。液体制剂可以包含雷帕霉素或其它治疗剂。

9. 发明申请

US20050244462A1 Devices and methods for treating a mammalian eye 审中-公开
标题翻译：用于治疗哺乳动物眼睛的装置和方法
公开(公告)号：US20050244462A1
公开(公告)日：2005-11-03
申请号：US10836908
申请日：2004-04-30
申请人： Sidiq Farooq
发明人： Sidiq Farooq
IPC分类号： A61F2/16 , A61F9/00 , A61F2/00
CPC分类号： A61F9/0017
摘要： Devices and methods for delivering a therapeutically active ocular implant into an eye are provided. Such a device generally includes a hollow sleeve having an open proximal end, a distal end, a substantially uniform inner diameter and a substantially uniform outer diameter extending between the proximal end and the open distal end. In addition, the device includes a plunger element having an angled configuration and sized to be slidably received within the sleeve for urging an implant from the distal end of the sleeve and into an eye. Systems for performing ocular research are provided which include a plurality of such hollow sleeves cut from a single flouroplastic tube, and a plurality of plunger elements cut from a single wire. The devices, systems and methods are especially useful for facilitating implantation of relatively fragile, for example brittle, ocular implants in an intact condition.
摘要翻译：提供了将治疗上有效的眼部植入物递送到眼睛中的装置和方法。这种装置通常包括中空套筒，其具有在近端和开口远端之间延伸的敞开的近端，远端，基本均匀的内径和基本均匀的外径。此外，该装置包括具有成角度构造并且尺寸设计成能够可滑动地容纳在套筒内的柱塞元件，用于将植入物从套筒的远端推入眼睛。提供了用于执行眼睛研究的系统，其包括从单个光塑管切割的多个这样的空心套管以及从单个线切割的多个柱塞元件。装置，系统和方法对于便于在完整状态下植入相对脆弱的，例如脆性眼部植入物是特别有用的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式